Question · asked by 1 review

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids): Avoidance of surgery ‐ number of patients who had surgery as rescue treatment

Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).

What each review found

Include earlier review versions
FindingEffectStudiesGRADE certainty
Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)
Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps
Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).
Biologics for chronic rhinosinusitis (2021) · Cochrane Headline outcomes only
RR 0.17 [0.05, 0.52]2 studies · 725 participantsModerate

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Biologics for chronic rhinosinusitis
2021 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.